Biotechnology company · INCY

Incyte
clinical trial
pipeline

Registry checked

Published

povorcitinib is linked to 8 distinct active studies, with 2 Phase 2, 6 Phase 3. Ruxolitinib is linked to 7 distinct active studies, with 1 Phase 1, 1 Phase 2, 5 Phase 3.

6 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

60active trials
as lead sponsor
  • Phase 118
  • Phase 216
  • Phase 323
  • Phase 40
  • Phase not recorded3

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

179 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Direction uncertain at the recorded date precision by 0 days

2026-09-30 (estimated)2026-09-30 (actual)

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

NCT05879822 · ClinicalTrials.gov
Recorded by ComplyRx
20 Oct 2026
Registry last updated
20 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-021000011
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000221
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-101110031
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-141010021
2026-10-150100011
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-202200042
2026-10-210000221
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-291010021
2026-10-300000000
2026-10-310000000
Type totals64304179 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

povorcitinib

Canonical investigational asset

8
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 22
  • Phase 36
  • Phase 40
  • Phase not recorded0
Studied condition
Hidradenitis Suppurativa (HS) · Moderate to Severe Asthma · NonSegmental Vitiligo
Next primary completion
20 November 2026 · estimated
Open drug

Ruxolitinib

JAKAFI · OPZELURA

7
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 21
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Atopic Dermatitis · Breast Cancer · Colorectal Cancer (CRC)
Next primary completion
30 April 2027 · estimated
Open drug

Axatilimab

niktimvo

6
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Chronic Graft-versus-host-disease
Next primary completion
06 January 2027 · estimated
Open drug

tafasitamab

monjuvi

6
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Diffuse Large B Cell Lymphoma · Diffuse Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma
Next primary completion
29 August 2027 · estimated
Open drug

INCB123667

Canonical investigational asset

5
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 21
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Hepatic Insufficiency · Liver Diseases · Ovarian Cancer
Next primary completion
27 April 2027 · estimated
Open drug

INCB161734

Canonical investigational asset

5
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 14
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy Participants · Hepatic Insufficiency · Kidney Diseases
Next primary completion
Not reported
Open drug

57 of 60 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 57 of 60 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Incyte trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Parsaclisib

NCT04509700

Phase 2 · Active, not recruiting

Trial source and qualifications

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

Start clipped at the display horizon.

4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

4 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 03 Aug 2020 · actual
    Primary completion: 05 Nov 2026 · estimated
    Study completion: 05 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
    povorcitinib

    NCT05851443

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

    5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    5 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 11 Jul 2023 · actual
      Primary completion: 20 Nov 2026 · estimated
      Study completion: 05 Jul 2027 · estimated

      2021202220232024202520262027202820292030
      STOP-HS LTE
      povorcitinib

      NCT06212999

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 30 Jan 2024 · actual
        Primary completion: 26 Dec 2026 · estimated
        Study completion: 26 Dec 2026 · estimated

        2021202220232024202520262027202820292030
        A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
        Axatilimab

        NCT06843408

        Phase 2 · Active, not recruiting

        Trial source and qualifications

        A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        4 candidate observations · 3 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

        • status flip · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • pc date moved · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • enrollment change · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 25 Jun 2025 · actual
        Primary completion: 06 Jan 2027 · estimated
        Study completion: 20 Jul 2028 · estimated

        2021202220232024202520262027202820292030
        MAESTRA 1
        INCB123667

        NCT07023627

        Phase 2 · Recruiting

        Trial source and qualifications

        A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 12 Nov 2025 · actual
          Primary completion: 27 Apr 2027 · estimated
          Study completion: 24 Oct 2027 · estimated

          2021202220232024202520262027202820292030
          A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
          Ruxolitinib

          NCT06804811

          Phase 3 · Recruiting

          Trial source and qualifications

          A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 13 Nov 2025 · actual
            Primary completion: 30 Apr 2027 · estimated
            Study completion: 01 Dec 2027 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 22 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 9 actual primary completions, 0 untyped primary completions, 5 past estimates, 3 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            28

            active trials in Oncology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Oncology28 trials
            • Dermatology11 trials
            • Immunology & Inflammation7 trials
            • Gastroenterology & Hepatology2 trials
            • Renal & Urology2 trials
            • Haematology1 trials
            • Respiratory1 trials
            • Unmapped6 trials
            • Healthy volunteers2 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            A

            AbbVie

            Shared indexed programme context · 1 selected asset

            N

            Novartis

            Shared indexed programme context · 1 selected asset

            R

            Roche

            Shared indexed programme context · 1 selected asset

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Canonical current-owner attribution covers 310 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Incyte Corporation. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            310 distinct registry candidates produced 310 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            292 scoped records have indexed enrichment and 18 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-11-01T00:45:15.122Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 9aee3602be8acedd3b5e0c6c9deea1354c38f49cfb4f0a0674dd7cc07362e820.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 310 mapped lead-sponsored clinical studies across all statuses. 292 have indexed enrichment, 18 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.